Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-18
2006-04-18
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S143100, C424S134100, C514S008100
Reexamination Certificate
active
07030080
ABSTRACT:
This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes comprising multiple subunits of lymphotoxin-β. These proteins and complexes are useful in holding LT-α formed within the cell on the cell surface where the LT-α/LT-β complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-α/LT-β complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-β.
REFERENCES:
patent: 4338397 (1982-07-01), Gilbert et al.
patent: 4758549 (1988-07-01), Mitsuhashi et al.
patent: 4822605 (1989-04-01), Powell
patent: 4849509 (1989-07-01), Thurin et al.
patent: 0367575 (1990-05-01), None
Browning et al., J. Exp. Med. vol. 183:867-878, 1996.
Mackay et al., J. Immunology vol. 159:3299-3310, 1997.
Browning et al., The Journal of Immunology. vol. 147(4):1230-1237, Aug. 15, 1991.
Abe, Y., et al. “Expression of membrane-associated lymphotoxin/tumor necrosis factor-beta on human lymphokine-activated killer cells.” Jpn J Cancer Res. 1991 Jan; 82(1):23-6.
Abe, Y., et al., “Studies of membrane-associated and soluble (secreted) lymphotoxin in human lymphokine-activated T-killer cells in vitro.”Lymphokine Cytokine Res. 1992 Apr; 11(2): 115-21.
Abersold, et al., “Internal amino acid sequence analysis of proteins separated by one-or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose.” PNAS. 1987; 84:6970-4.
Aggarwal, B.B., et al., “Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line.”J. Biol Chem. 1985 Feb. 25; 260(4):2334-44.
Akashi, M., et al. “Lymphotoxin: stimulation and regulation of colony-stimulating factors in fibroblast.”Blood. 1989 Nov. 15; 74(7)2383-90.
Anderson, W.F. “Human gene therapy.”Science. 1992 May 8; 256(5058):808-13.
Anderson, U., et al. “Characterization of individual tumor necrosis factor alpha-and beta-producing cells after polyclonal T cell activation.”J. of Immun. Meth. 1989; 123:233-40.
Andrews, J.S., et al. “Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes.”J Immunol. 1990 Apr. 1; 144(7):2582-91.
Androlewicz, M.J., et al. “Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma.”J Biol Chem. 1992 Feb. 5; 267(4):2542-7.
Armitage, R.J., et al. “Molecular and biological characterization of a murine ligan for CD40.”Nature. 1992 May 7; 357(6373):80-2.
Badenhoop, K., et al. “TNF-alpha gene polymorphisms in type 1 (insulin-dependent) diabetes mellitus.”Diabetologia. 1989 Jul; 32(7):445-8.
Beutler, B., et al. “The history, properties, and biological effects of cachectin.”Biochemistry. 1988 Oct. 4; 27(20):7575-82.
Bringman, T.S., et al. “Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoasays, and a s structural probes.”Hybridoma. 1987 Oct; 6(5):489-507.
Browning, J.L., et al. “Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines.”J. Immunol. 1989 Sep. 15; 143(6):1859-67.
Browning, J.L, et al. “Lymphotoxin and an associated 33-kDa glycoprotein are expressed on the surface of an activated human T cell hybridoma,”J Immunol. 1991 Aug. 15; 147(4):1230-7.
Cavender, D.E., et al. “Endothelial cell activation induced by tumor necrosis factor and lymphotoxin.”Am. J Pathol. 1989 Mar; 134(3):551-60.
Cotran, R.S., et al. “Endothelial activation, its role in inflammatory and immune reactions.”Endothelial Cell Biology. 1988; 335-47.
Damle, N.K., et al. “District regulatory effects of IL-4 and TNF-alpha during CD3-dependent and CD3-independent initiation of human T-cell activation.”Lymphokine Res. 1989; 8(2):85-97.
Eck, M.J. et al., “The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding.”J. Biol. Chem. 1989 Oct. 15; 264(29):17595-605.
Eck, M.J. et al. “The structure of human lynmphotoxin (tumor necrosis factor-beta) at 1.9-A resolution.”J. Biol Chem. 1992 Feb. 5; 267(4):2119-22.
Farrah, T., et al. “Emerging cytokine family.”Nature. 1992 Jul. 2; 358(6381):26.
Fuh, G., et al., “Rational design of potent antagonists to the human growth hormone receptor.”Science. 1992 Jun. 19: 256(5064):1677-80.
Goeddel, D.V., et al. “Tumor necrosis factors: gene structure and biological activities.”Cold Spring Harb Symp Quant Biol. 1986; 51:597-609.
Granger, G.A., et al. “Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction.”J Immunol. 1968 Jul; 101(1):111-20.
Gray, P.W. “Molecular characterization of human lymphotoxin.”Lumphokines. 1987; 13:199-208.
Gray, P.W., et al. “Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity.”Nature. 1984 Dec. 20-1985 Jan. 2; 312(5996):721-4.
Green, L.M. et al. “Cytotoxic lymphokines produced by cloned human cytotoxic T lymphocytes. I. Cytotoxins produced by antigen-specific and natural killer-like CTL are dissimilar to classical lymphotoxins.”J Immunol. 1985 Dec; 135(6):4034-43.
Green, L.M., et al. “Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.”J Immunol Methods. 1984 May 25; 70(2):257-68.
Hiserodt, J.C. et al. “Identification of membrane-associated lymphotoxin (LT) on mitogen-activated human lymphocytes using heterologous anti-LT antisera in vitro.”Cell Immunol. 1977 Dec; 34(2):326-39.
Itoh, N., et al., “The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.”Cell. 1991 Jul. 26; 66(2):233-43.
Jones, E.Y., et al. “Structure of tumnour necrosis factor.”Nature. 1989 Mar. 16; 338(6212):225-8.
Kasid, A., et al. “Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.”Proc Natl Sci USA. 1990 Jan; 87(1):473-7.
Kinkhabwala, M., et al. “A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachetin by activate normal human T cells.”J Exp Med. 1990 Mar. 1; 171(3):941-6.
Krieglr, M., et al. “A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF.”Cell. 1988 Apr. 8; 53(1):45-53.
Liang, C.M., et al. “Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin.”Biochem Biophys Res Commun. 1986 Jun. 13; 137(2):847-54.
Liu, C.C., et al. “Identification, isolation, and characterization of a novel cytotoxin in murine cytolytic lymphocytes.”Cell. 1987 Nov. 6; 51(3):393-403.
Liu, C.C. et al. “Identification and characterization of a membrane-bound cytotoxin of murine cytolytic lymphocytes that is related to tumor necrosis factor/cachectin.”Proc Natl Acad Sci USA. 1989 May: 86(9):3286-90.
Luetig, B., et al. “Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor.”J Immunol. 1989 Dec. 15; 143(
Browning Jeffrey
Ware Carl F.
Biogen Inc.
Lahive & Cockfield
Mandragouras Amy
McGarry Sean
University of California
LandOfFree
Lymphotoxin-β, lymphotoxin-β complexes,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lymphotoxin-β, lymphotoxin-β complexes,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphotoxin-β, lymphotoxin-β complexes,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3603847